iOnctura expands PI3K inhibitor programme to NSCLC

iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase II trial.

Jul 10, 2024 - 04:00

iOnctura expands PI3K inhibitor programme to NSCLC

iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase II trial.

Read the original article

Tags:

Previous Article

Exponentially increasing understanding of early life on Earth

iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

ICR to enter AI-powered cancer drug discovery partnership

ICR to enter AI-powered cancer drug discovery partnership

Jul 13, 2023

CT-080 by First Condor Group for Gastric Cancer: Likeli...

Oct 3, 2023

How SaaS platforms are breaking the mold for clinical trials

How SaaS platforms are breaking the mold for clinical t...

Aug 7, 2024